NuProbe VarTrace Sanger Assays

NuProbe Global has launched VarTrace Sanger assays for ultrasensitive detection and quantification of cancer mutations with variant allele frequencies down to 0.1 percent. The company specifically launched three assays covering EGFR mutations for non-small-cell lung cancer; BRAF mutations for melanoma and thyroid cancer; and FLT3, DNMT3A, IDH1, IDH2, KIT, NPM1 mutations for acute myeloid leukemia. The assays are based on the firm's proprietary blocker displacement amplification (BDA) technology, and are compatible with both cell-free DNA from blood plasma and tissue samples including formalin-fixed paraffin-embedded tissue, NuProbe said.